Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2002

View Archived Issues

Celltech receives CDP-870 phase III milestone payment from Pharmacia

Embosphere Microspheres approved for treatment of uterine fibroid

PCL-016 enters phase IIa in acne

GenVec initiates phase I trial of AdPEDF in AMD

eXegenics and IDDS terminate merger agreement

Abbott and MerLion collaborate on natural product-based drug discovery

Photogen to acquire medical imaging assets from Alliance

Gruenenthal presents novel siderophores for delivering antibacterial agents

Phosphodiesterase inhibitors discovered at Ortho-McNeil

Bayer researchers present novel anticytomegalovirus agents

New ciclosporin prodrugs with utility in ocular disorders

Two series of TNF-alpha production inhibitors identified at Sanofi-Synthelabo

Gemin X's Bcl-2 inhibitors are effective proapoptotic and antitumor compounds

New nonanticoagulant heparin derivatives retain antiangiogenic/antitumor activity

CJ-13610: design of an orally active and safe 5-LO inhibitor

Long-acting, oral DPP-IV inhibitor and hypoglycemic agent presented in Shizuoka

Effective agents for nephritis without cardiovascular side effects designed at Tanabe Seiyaku

Potent anti-HIV agents targeting viral protease designed by U.S./Japanese team

Novartis files marketing applications for Prexige

NDA for palonosetron accepted for filing by the FDA

Lilly receives FDA approval for Strattera

Teriparatide approved by the FDA to treat osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...